Abstract
Classical consequence of treatment with anti-diabetic agents, including insulin, is weight gain which enhances insulin resistance and leads to a further increase in drug dose. This creates an unwanted cycle.
Administration of weight neutral anti-diabetic drugs has broken this scenario. Another option is to use anti-obesity agents, but actually many of them are not available.
However, in the United States, two new drugs have been used in past two years. The most important change in the treatment of obese type 2 diabetes patients is administration of anti-diabetic agents that reduce weight.
These agents are well-known incretin analogs characterized by their unpleasant injecting administration. However, application becomes easier and the drugs are administered for the866 longer time period.
Even greater change in treatment is administration of gliflozins. Dapagliflozin and empagliflozin enter almost simultaneously to the Czech Republic.
The new class of drugs has very complex metabolic effect and in particular significantly reduces the weight even in patients treated with insulin. The treatment options have significantly expanded for obese type 2 diabetes patient in course of this year.